EuroAPI Header EuroAPI Header

X
[{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","amount":"$61.3 million","upfrontCash":"Undisclosed","newsHeadline":"French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac\u00ae and Parkinane\u00ae LP to CNX Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Loxapine Succinate

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Through the divestment, the company has acquired the rights and will concentrate on commercializing Loxacin (loxapine succinate) for treating psychotic disorders and personality disorders.

            Lead Product(s): Loxapine Succinate

            Therapeutic Area: Psychiatry/Psychology Product Name: Loxapac

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CNX Therapeutics

            Deal Size: $61.3 million Upfront Cash: Undisclosed

            Deal Type: Divestment April 02, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY